Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3013 in Healthy Participants, Vitiligo, and Alopecia Areata
NCT07554222Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3013 in Vitiligo and alopecia areata (3 arms), sponsored by Innovent Biologics. Primary endpoints: Number of participants with at least one treatment-emergent adverse event at 48 weeks and Number of participants with at least one Serious treatment-emergent adverse event at 48 weeks. Started Apr 2026; status: recruiting.
02
Drugs
IBI3013
03
Conditions
Vitiligoalopecia areata
Beyond the preview
Go deeper on NCT07554222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07554222.